Home » Stocks » ZLAB

Zai Lab Limited (ZLAB)

Stock Price: $86.08 USD -2.42 (-2.73%)
Updated Oct 28, 2020 2:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 7.40B
Revenue (ttm) 12.99M
Net Income (ttm) -195.07M
Shares Out 85.94M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $86.08
Previous Close $88.49
Change ($) -2.42
Change (%) -2.73%
Day's Open 87.42
Day's Range 83.27 - 87.73
Day's Volume 237,583
52-Week Range 30.01 - 95.52

More Stats

Market Cap 7.40B
Enterprise Value 7.14B
Earnings Date (est) May 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 85.94M
Float 81.62M
EPS (basic) -3.03
EPS (diluted) -3.39
FCF / Share -3.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.52M
Short Ratio 7.09
Short % of Float 4.31%
Beta 0.95
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 569.68
PB Ratio 16.19
Revenue 12.99M
Operating Income -202.26M
Net Income -195.07M
Free Cash Flow -204.88M
Net Cash 254.15M
Net Cash / Share 2.96
Gross Margin 32.09%
Operating Margin -1,557.63%
Profit Margin -1,502.30%
FCF Margin -1,577.84%
ROA -31.12%
ROE -55.99%
ROIC -88.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 9
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$99.01*
(15.03% upside)
Low
90.0
Current: $86.08
High
111.0
Target: 99.01
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue12.990.13---
Revenue Growth9965.89%----
Gross Profit9.240.09---
Operating Income-202-142-50.86-36.00-16.05
Net Income-195-139-50.38-37.51-18.02
Shares Outstanding64.3752.6121.759.448.69
Earnings Per Share-3.03-2.64-2.32-3.97-2.07
Operating Cash Flow-191-97.54-32.37-32.16-11.46
Capital Expenditures-13.87-10.02-9.02-2.22-0.74
Free Cash Flow-205-108-41.39-34.38-12.20
Cash & Equivalents27626323083.9513.16
Total Debt21.783.64---
Net Cash / Debt25426023083.9513.16
Assets35530225088.9113.94
Liabilities60.4950.9114.465.954.00
Book Value295251235-51.55-18.37
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zai Lab Limited
Country China
Employees 859
CEO Ying Samantha Du

Stock Information

Ticker Symbol ZLAB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZLAB
IPO Date September 20, 2017

Description

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.